 
| |
|
|
| press releases
| | |
| | |
|
| Date: |
Title: |
| January 7 , 2008 |
TransMolecular Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Malignant Glioma |
| November
19 , 2007 |
TransMolecular
Reports Positive Phase 2 Data from Study of  Iodine
Radiolabeled TM-601 in Recurrent Glioma |
| October
31, 2007 |
TransMolecular
Reports Positive Phase 1 Trial of Iodine
Radiolabeled TM-601 in Glioma |
| October
24, 2007 |
TransMolecular,
Inc. Announces Formation of Medical Advisory Board |
| October
19, 2007 |
TransMolecular,
Inc. Names Morphotek Executive Nicholas C. Nicolaides,
Ph.D., Chairman of the Board |
| July
28, 2006 |
Synthetic
Version of Scorpion Venom Delivers Radioactive Iodine to Malignant
Brain Tumors |
| June,
5, 2006 |
Study
Demonstrates Safety of Promising Investigational Treatment
for Deadly Brain Cancer |
| June
9, 2005 |
TransMolecular
Appoints E. Michael Egan As Chief Executive Officer |
| June
1, 2005 |
TransMolecular
Launches Phase II Clinical Study of I-TM-601
to Treat Deadly Form of Brain Cancer |
| May
10, 2005 |
Board
Changes Signal Continued Growth at TransMolecular |
| November
17, 2004 |
TransMolecular
Broadens Patent Portfolio for Lead Oncology Products with
Fifth Issued U.S. Patent |
| November
9, 2004 |
TransMolecular
Obtains Patent for Key Biological Target Involved in Chronic
Pain |
| August
27, 2003 |
TransMolecular
Receives FDA Fast Track Designation forI-TM-601,
Its Lead Compound for Brain Cancer |
| September
4, 2002 |
TransMolecular
Receives Patents to Protect Composition of Matter and Methods
of Treating Cancer |
| June
27, 2002 |
FDA
Grants TransMolecular Orphan Drug Designation forI-TM-601
for Use by Glioma Patients |
| April
1, 2002 |
TransMolecular,
Inc. Receives FDA Approval forI-TM-601
IND Application |
archived
press releases
|
|
|
|
|
| | | | | |
|
| | | | |
| | | | | |
|
|
|
| | |
|
| |
